/
Psychiatry
Attention Deficit Hyperactivity Disorder
15
Pipeline Programs↗
34
Active Trials↗
41
Companies Involved↗
Attention Deficit Hyperactivity Disorder is an emerging landscape with 15 programs across 41 companies. The most active players are Otsuka, Supernus Pharmaceuticals, Inc.. 5 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical10
Phase 1
No programs
Phase 2
No programs
Phase 35
Approved
No programs
Analysis
Trial Status
257
clinical trials
Completed187 · 73%
Recruiting20 · 8%
Unknown status18 · 7%
Terminated12 · 5%
Not yet recruiting8 · 3%
Active, not recruiting6 · 2%
Other6 · 2%
Clinical Trials
Trial Activity
257 trials
Virtual Reality in Rehabilitation of Executive Functions in Children (VREALFUN)
Recruiting·—·Preclinical·NCT06123741·88 enrolled
Page 1 of 18
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)